Hypertension is a risk factor for accelerated saphenous vein (SV) graft disease and endothelial dysfunction in a number of vascular territories. We examined the relationship between blood pressure (BP) and vascular function in SV from 94 male patients undergoing coronary artery bypass grafting (CABG). Patients were pretreated with respect to cholesterol (3.4±1.2 mmol/L) and BP (systolic 139±22 mmHg, diastolic 74±13 mmHg). All patients were taking aspirin, 85% statins, 50% angiotensin-converting enzyme inhibitors and 70% beta-blockers. We demonstrate in human SV rings ex vivo that increased BP has no effect on acetylcholine-mediated vasodilatation (p=0.58), nor on the constrictor response to L-NMMA (p=0.98), but has a positive association with the constrictor response to phenylephrine (p=0.008) and a negative correlation with the vasodilator response to sodium nitroprusside (p=0.03). These results may provide further explanation for the high incidence of early vein graft failure after CABG in hypertensive patients and support an aggressive approach to optimize BP before surgery.
DavisKBChaitmanBRyanT. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS (Coronary Artery Surgery Study) registry study. J Am Coll Cardiol1995; 25: 1000–1009.
2.
CanosDAMintzGSBerzingiCO. Clinical, angiographic, and intravascular ultrasound characteristics of early saphenous vein graft failure. J Am Coll Cardiol2004; 44: 53–56.
3.
CampeauLEnjalbertMLesperanceJ. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Eng J Med1984; 311: 1329–1332.
4.
BourassaM. The fate of venous grafts: the past, the present and the future. J Am Coll Cardiol1991; 5: 1081–1083.
5.
GoldmanSZadinaKMoritzT. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery. Results from the Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol2004: 44: 2149–2156.
6.
WeintraubWJonesECraverJ. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous vein grafts. Am J Cardiol1994; 73: 103–112.
CableDGCaccitoloJACapliceN. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation1999; 100: II-392-II-396.
9.
DomanskiMJBorkowfCBCampeauL. Prognostic factors for atherosclerosis progression in saphenous vein grafts. The postcoronary artery bypass graft (Post-CABG) Trial. J Am Coll Cardiol2000; 36: 1877–1883.
10.
ShahPJGordonIFullerJ. Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg2003; 126: 1972–1977.
11.
PanzaJAQuyyumiAABrushJEJrEpsteinSE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med1990; 323: 22–27.
12.
BenjaminEJLarsonMGKeyesMJ. Clinical correlates and heritability of flow-mediated dilation in the community: The Framingham Heart Study. Circulation2004; 109: 613–619.
13.
TreasureCBManoukianSVKleinJL. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res1992; 71: 776–781.
14.
CockroftJRChowienczykPJBenjaminN. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med1994; 330:1036–1040.
15.
GuzikTJWestNEJBlackE. Vascular superoxide production by NAD(P)H oxidase association with endothelial dysfunction and clinical risk factors. Circ Res2000; 86: e85–e90.
16.
RossR. Atherosclerosis is an inflammatory disease. N Eng J Med1999; 340: 115–126.
MonastyrskayaEFolarinNMalyshev. Application of the nitric oxide donor SNAP to cardiomyocytes in culture provides protection against oxidative stress. Nitric Oxide2002; 7: 127–131.
19.
GargUCHassidA. Nitric oxide-generating vasodilators and 8-bromo cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest1989; 83: 1774–1777.
20.
SchaferAWiesmannFNeubauerS. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation2004; 109: 1819–1822.
21.
CreagerMACookeJPMendelsohnME. Impaired vasodilation of forearm resistance vessels in hypercholesterolaemia humans. J Clin Invest1990; 86: 228–234.
22.
SchachingerVBrittenMBZeiherAM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation2000; 101: 1899–1906.
23.
BugiardiniRManfriniOPizziC. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation2004; 109: 2518–2523.
24.
ShapiraOMXuAAldeaGS. Enhanced nitric oxide-mediated vascular relaxation in radial artery compared with internal mammary artery or saphenous vein. Circulation1999; 100: II322–II327.
25.
DoyleAEBlackAE. Reactivity to pressor agents in hypertension. Circulation1955; 12: 974–980.
26.
GwirtzPA. Coronary alpha1-vasoconstrictor tone during renovascular hypertension. Circulation1997; 92: 1576–1581.
CoxJLChiassonDAGotliebAI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis1991; 34: 45–68.
29.
StaryHCBlankenhornDHBleakley ChandlerA. A definition of the intima of human arteries and its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation1992; 85: 391–405.
30.
PregowskiJTycznskiPMintzGS. Incidence and clinical correlates of ruptured plaques in saphenous vein grafts: an intravascular ultrasound study. J Am Coll Cardiol2005; 45: 1974–1979.
